Ociperlimab
As of the edition of 20 October 2026, Ociperlimab is an antibody: stopped in 2026; acts on TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody
- Registered trials
- 13, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Ociperlimab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | Q495A1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 8 | 7 | 0 | 1 |
| Phase 3 | 4 | 1 | 0 | 3 |
| All trials | 13 |